Novo Nordisk (NVO) reported Q2 earnings Wednesday of 5.96 Danish kroner ($0.92) per diluted share, up from 4.49 Danish kroner a year earlier.
Analysts polled by FactSet expected 5.92 Danish kroner.
Revenue for the quarter ended June 30 was 76.86 billion Danish kroner, compared with 68.06 billion Danish kroner a year earlier.
Analysts surveyed by FactSet expected 76.73 billion Danish kroner.
The company lowered its 2025 sales growth guidance to 8% to 14% from the previous range of 13% to 21% driven by lower growth expectations for its GLP-1 treatments in H2 2025. Analysts surveyed by FactSet expected 318.99 billion Danish kroner.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments